sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
risperidone
|
triazolam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p994
|
Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
|
Urinary acidifying agents
|
amphetamine
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s1
|
DDI-DrugBank.d236.s1.p2
|
Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
|
Amphetamines
|
phenobarbital
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s19
|
DDI-DrugBank.d158.s19.p2
|
- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
|
sulfamethoxazole
|
Bactrim
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s3
|
DDI-DrugBank.d521.s3.p1
|
Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.
|
Trecator
|
antituberculous drugs
|
EFFECT
|
Ethionamide_ddi.xml
|
DDI-DrugBank.d166.s1
|
DDI-DrugBank.d166.s1.p0
|
Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
|
antianxiety agents
|
hydrocodone
|
EFFECT
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s0
|
DDI-DrugBank.d396.s0.p13
|
This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
|
celecoxib
|
fluconazole
|
MECHANISM
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s17
|
DDI-DrugBank.d172.s17.p0
|
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.
|
pyreneperone
|
apomorphine
|
NONE
|
2857100.xml
|
DDI-MedLine.d15.s0
|
DDI-MedLine.d15.s0.p29
|
Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
|
Aprepitant
|
dexamethasone
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s9
|
DDI-DrugBank.d382.s9.p18
|
Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
|
fexofenadine hydrochloride
|
Maalox
|
MECHANISM
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s19
|
DDI-DrugBank.d466.s19.p9
|
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
|
Lithium
|
lithium
|
NONE
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s18
|
DDI-DrugBank.d175.s18.p2
|
Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.
|
probenecid
|
PAH
|
EFFECT
|
Aminohippurate_ddi.xml
|
DDI-DrugBank.d416.s3
|
DDI-DrugBank.d416.s3.p0
|
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
|
phenothiazines
|
APOKYN
|
EFFECT
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s3
|
DDI-DrugBank.d357.s3.p38
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Kaletra
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p28
|
Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
|
carbamazepine
|
carbamazepine
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s22
|
DDI-DrugBank.d568.s22.p5
|
This may occur because diflunisal competitively displaces coumarins from protein binding sites.
|
diflunisal
|
coumarins
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s1
|
DDI-DrugBank.d132.s1.p0
|
Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
|
Ponstel
|
aspirin
|
ADVISE
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s0
|
DDI-DrugBank.d400.s0.p5
|
These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication.
|
clozapine
|
PCP
|
NONE
|
11114408.xml
|
DDI-MedLine.d135.s6
|
DDI-MedLine.d135.s6.p0
|
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
|
antidepressants
|
Type 1C antiarrhythmics
|
NONE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s15
|
DDI-DrugBank.d238.s15.p6
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
ethacrynic acid
|
methylphenidate
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p863
|
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
|
lithium
|
ACE inhibitor
|
EFFECT
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s18
|
DDI-DrugBank.d175.s18.p9
|
Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.
|
nonsteroidal anti inflammatory drug
|
quinolone
|
EFFECT
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s19
|
DDI-DrugBank.d78.s19.p5
|
therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
|
lansoprazole
|
ketoconazole
|
MECHANISM
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s12
|
DDI-DrugBank.d431.s12.p0
|
Misonidazole has a complex effect on oral CCNU pharmacokinetics.
|
Misonidazole
|
CCNU
|
MECHANISM
|
3966974.xml
|
DDI-MedLine.d85.s9
|
DDI-MedLine.d85.s9.p0
|
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
|
phenytoin
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s18
|
DDI-DrugBank.d314.s18.p7
|
The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
|
dextromethorphan hydrobromide
|
alcohol
|
EFFECT
|
Guaifenesin_ddi.xml
|
DDI-DrugBank.d398.s2
|
DDI-DrugBank.d398.s2.p0
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
levodopa
|
lovastatin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p456
|
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
|
dexamethasone
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s4
|
DDI-MedLine.d12.s4.p1
|
Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
|
EQUETROTM
|
primidone
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s13
|
DDI-DrugBank.d94.s13.p7
|
ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
|
NSAIDs
|
Angiotensin Converting Enzyme (ACE) inhibitors
|
EFFECT
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s0
|
DDI-DrugBank.d210.s0.p2
|
Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.
|
Alcohol
|
aspirin
|
EFFECT
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s1
|
DDI-DrugBank.d443.s1.p0
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
somatropin
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p10
|
Specific Effects of Felbatol on Other Antiepileptic Drugs Phenytoin: Felbatol causes an increase in steady-state phenytoin plasma concentrations.
|
Felbatol
|
Felbatol
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s11
|
DDI-DrugBank.d434.s11.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
atorvastatin
|
Lipitor
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p612
|
It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
|
ampicillin
|
allopurinol
|
EFFECT
|
Clavulanate_ddi.xml
|
DDI-DrugBank.d419.s1
|
DDI-DrugBank.d419.s1.p0
|
Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.
|
Lodine
|
aspirin
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s4
|
DDI-DrugBank.d219.s4.p3
|
Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.
|
rifampicin
|
erlotinib
|
MECHANISM
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s2
|
DDI-DrugBank.d456.s2.p0
|
Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
|
Phospholine Iodide
|
succinylcholine
|
EFFECT
|
Echothiophate Iodide_ddi.xml
|
DDI-DrugBank.d377.s0
|
DDI-DrugBank.d377.s0.p1
|
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
|
Multivitamins
|
norfloxacin
|
ADVISE
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s11
|
DDI-DrugBank.d217.s11.p4
|
Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
|
dopamine HCl
|
halogenated hydrocarbon anesthetics
|
ADVISE
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s10
|
DDI-DrugBank.d325.s10.p1
|
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
|
benzodiazepines
|
macrolide antibiotics
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s8
|
DDI-DrugBank.d338.s8.p5
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
hydrochlorothiazide
|
aliskiren
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p55
|
Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
|
quinolone class antimicrobial
|
fenbufen
|
EFFECT
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s10
|
DDI-DrugBank.d562.s10.p1
|
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.
|
diltiazem
|
sirolimus
|
NONE
|
11180036.xml
|
DDI-MedLine.d86.s5
|
DDI-MedLine.d86.s5.p2
|
Potential drug interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
|
AEDs
|
carbamazepine
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s11
|
DDI-DrugBank.d212.s11.p10
|
Orlistat-Orlistat may decrease the absorption of vitamin K.
|
Orlistat
|
vitamin K
|
MECHANISM
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s6
|
DDI-DrugBank.d139.s6.p2
|
- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;
|
HCTZ
|
Hydrodiuril
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s6
|
DDI-DrugBank.d521.s6.p9
|
Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.
|
zalcitabine
|
metoclopramide
|
MECHANISM
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s24
|
DDI-DrugBank.d263.s24.p2
|
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
|
miconazole
|
hypoglycemic agents
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s9
|
DDI-DrugBank.d245.s9.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
cimetidine
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p10
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
diazepam
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p4
|
Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.
|
ATROVENT
|
anticholinergic
|
ADVISE
|
Ipratropium_ddi.xml
|
DDI-DrugBank.d51.s3
|
DDI-DrugBank.d51.s3.p0
|
May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;
|
colestipol
|
thiazide diuretics
|
EFFECT
|
Bendroflumethiazide_ddi.xml
|
DDI-DrugBank.d304.s0
|
DDI-DrugBank.d304.s0.p3
|
Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.
|
Neuroleptic Drugs
|
L-phenylalanine
|
EFFECT
|
L-Phenylalanine_ddi.xml
|
DDI-DrugBank.d530.s3
|
DDI-DrugBank.d530.s3.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
prolonged narcotics
|
trimethoprim
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1391
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
valproate
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p10
|
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
|
Erythromycin
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s3
|
DDI-DrugBank.d450.s3.p3
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
vitamin D
|
Calcidiol
|
NONE
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s0
|
DDI-DrugBank.d404.s0.p3
|
Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;
|
vitamin C
|
synthetic estrogens
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s14
|
DDI-DrugBank.d485.s14.p5
|
Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
|
Magnesium
|
vitamin D
|
ADVISE
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s15
|
DDI-DrugBank.d384.s15.p4
|
Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.
|
Beta-adrenergic blocking agents
|
arbutamine
|
ADVISE
|
Arbutamine_ddi.xml
|
DDI-DrugBank.d253.s1
|
DDI-DrugBank.d253.s1.p0
|
Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
Lodine
|
furosemide
|
EFFECT
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s11
|
DDI-DrugBank.d219.s11.p0
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
nabumetone
|
oxaprozin
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p273
|
Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
|
TRISENOX
|
thioridazine
|
ADVISE
|
Arsenic trioxide_ddi.xml
|
DDI-DrugBank.d470.s1
|
DDI-DrugBank.d470.s1.p1
|
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
|
Antihistamines
|
hypnotics
|
EFFECT
|
Cyproheptadine_ddi.xml
|
DDI-DrugBank.d492.s1
|
DDI-DrugBank.d492.s1.p2
|
Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.
|
nonsteroidal anti-inflammatory drugs
|
furosemide
|
EFFECT
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s14
|
DDI-DrugBank.d529.s14.p5
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
beta adrenergic blocking agents
|
EFFECT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p8
|
H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
|
H1 Blockers
|
L-histidine
|
NONE
|
L-Histidine_ddi.xml
|
DDI-DrugBank.d365.s1
|
DDI-DrugBank.d365.s1.p1
|
Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
|
fluvoxamine
|
astemizole
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s11
|
DDI-DrugBank.d76.s11.p1
|
Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
|
Aprepitant
|
S(-) warfarin
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s4
|
DDI-DrugBank.d382.s4.p0
|
Caution should be used if naproxen is administered concomitantly with methotrexate.
|
naproxen
|
methotrexate
|
ADVISE
|
Naproxen_ddi.xml
|
DDI-DrugBank.d85.s11
|
DDI-DrugBank.d85.s11.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Topamax
|
antifungals
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p430
|
There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum digoxin concentration.
|
quinine
|
penicillamine
|
NONE
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s8
|
DDI-DrugBank.d450.s8.p0
|
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.
|
glycine
|
glutamate
|
EFFECT
|
7794883.xml
|
DDI-MedLine.d20.s4
|
DDI-MedLine.d20.s4.p0
|
Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
|
Tetracycline
|
bacteriostatic antibiotic
|
NONE
|
Nafcillin_ddi.xml
|
DDI-DrugBank.d261.s0
|
DDI-DrugBank.d261.s0.p0
|
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
|
desipramine
|
chlordiazepoxide
|
EFFECT
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s23
|
DDI-DrugBank.d386.s23.p31
|
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
|
hypnotics
|
antigout drugs
|
NONE
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s12
|
DDI-DrugBank.d507.s12.p25
|
Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
|
dipyrone
|
aspirin
|
EFFECT
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s3
|
DDI-DrugBank.d443.s3.p9
|
Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
|
clonidine
|
calcium channel blockers
|
ADVISE
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s7
|
DDI-DrugBank.d495.s7.p1
|
Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
|
erythromycin
|
digoxin
|
MECHANISM
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s2
|
DDI-DrugBank.d397.s2.p0
|
Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.
|
Chlorthalidone
|
antihypertensive drugs
|
EFFECT
|
Chlorthalidone_ddi.xml
|
DDI-DrugBank.d265.s0
|
DDI-DrugBank.d265.s0.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
bacitracin
|
sodium colistemethate
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p69
|
Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
|
Dipyridamole
|
adenosine
|
MECHANISM
|
Dipyridamole_ddi.xml
|
DDI-DrugBank.d505.s2
|
DDI-DrugBank.d505.s2.p2
|
Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
|
allopurinol
|
thiazide diuretics
|
EFFECT
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s12
|
DDI-DrugBank.d413.s12.p3
|
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
|
clarithromycin
|
Rifabutin
|
NONE
|
Delavirdine_ddi.xml
|
DDI-DrugBank.d251.s0
|
DDI-DrugBank.d251.s0.p6
|
Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
|
sodium acid phosphate
|
amphetamine
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s1
|
DDI-DrugBank.d236.s1.p5
|
Concomitant use of zalcitabine and lamivudine is not recommended.
|
zalcitabine
|
lamivudine
|
ADVISE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s9
|
DDI-DrugBank.d263.s9.p0
|
Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
|
astemizole
|
ketoconazole
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s7
|
DDI-DrugBank.d76.s7.p4
|
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
|
clarithromycin
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s3
|
DDI-DrugBank.d450.s3.p8
|
TCAs decrease the hypotensive effect of guanfacine.
|
TCAs
|
guanfacine
|
EFFECT
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s4
|
DDI-DrugBank.d507.s4.p0
|
therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
|
ampicillin
|
iron
|
NONE
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s12
|
DDI-DrugBank.d431.s12.p7
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
androgens
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p0
|
Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
|
Cyclophosphamide
|
succinylcholine chloride
|
EFFECT
|
Cyclophosphamide_ddi.xml
|
DDI-DrugBank.d7.s2
|
DDI-DrugBank.d7.s2.p0
|
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.
|
tiagabine
|
tiagabine
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s15
|
DDI-DrugBank.d277.s15.p9
|
Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
|
halothane
|
NUROMAX
|
MECHANISM
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s3
|
DDI-DrugBank.d267.s3.p5
|
Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
|
theophylline
|
quinolone
|
MECHANISM
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s0
|
DDI-DrugBank.d217.s0.p0
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
vitamin D
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p11
|
Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
|
Aprepitant
|
midazolam
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s25
|
DDI-DrugBank.d382.s25.p1
|
The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
|
norepinephrine
|
Bretylium Tosylate
|
EFFECT
|
Bretylium_ddi.xml
|
DDI-DrugBank.d180.s1
|
DDI-DrugBank.d180.s1.p5
|
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
|
lithium
|
ACE inhibitors
|
NONE
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s7
|
DDI-DrugBank.d561.s7.p5
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.